MIRM (US) share price forecast & AI signal — Mirum Pharmaceuticals, Inc
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in MIRM
Mirum Pharmaceuticals, Inc is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a BUY with high confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Mirum Pharmaceuticals, Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $93.72 |
| 2026-11-05 | $93.54 |
| 2026-11-04 | $96.97 |
| 2026-11-03 | $87.03 |
| 2026-11-02 | $85.74 |
| 2026-10-30 | $85.00 |
| 2026-10-29 | $86.39 |
MIRM FAQ
Is Mirum Pharmaceuticals, Inc (MIRM) a buy or sell this week?
The ACE Stock Bots machine-learning model rates MIRM a BUY for the week of 2026-10-30 with high confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for MIRM?
Every week the model scores MIRM across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.